Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 3/20 | 1.00 |
| ▸ | HTR3A | P46098 | 2/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.52 |
| ▸ | HTR3B | O95264 | 1/20 | 0.52 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.52 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1041383 | 1.00 | HTR4 (1.00) | HTR4HTR3ATMEM97SIGMAR1HTR3E | |
| Hydrochloric Acid SCHEMBL8717464 | 0.99 | HTR4 (0.98) | HTR4HTR3ATMEM97SIGMAR1HTR3E | |
| Hydrochloric Acid SCHEMBL29386085 | 0.99 | HTR4 (0.98) | HTR4HTR3ATMEM97SIGMAR1HTR3E | |
| Hydrochloric Acid SCHEMBL9572388 | 0.98 | HTR4 (0.96) | HTR4HTR3ATMEM97SIGMAR1HTR3E | |
| Hydrochloric Acid SCHEMBL678218 | 0.98 | HTR4 (0.96) | HTR4HTR3ATMEM97SIGMAR1HTR3E | |
| SCHEMBL7389966 | 0.95 | HTR4 (0.91) | HTR4HTR3ATMEM97SIGMAR1HTR3E | |
| SCHEMBL7389967 | 0.95 | HTR4 (0.91) | HTR4HTR3ATMEM97SIGMAR1HTR3E | |
| SCHEMBL7343018 | 0.92 | HTR3A (0.85) | HTR4HTR3ATMEM97SIGMAR1HTR3E | |
| SCHEMBL9398539 | 0.92 | HTR3A (0.85) | HTR4HTR3ATMEM97SIGMAR1HTR3E | |
| SCHEMBL8947409 | 0.89 | HTR4 (0.80) | HTR4HTR3ATMEM97SIGMAR1HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1239882-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND 5HT3 AGONISTS | GLAXO GROUP LTD (GB) | 2004-09-29 | — | — | EP | claimed |
| US-20030018008-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-23 | — | — | US | claimed |
| EP-0567767-B1 | Crystalline forms of endo-2,3-dihydro-N-(8-methyl-8-azabicyclo (3.2.1)oct-3-yl)-2-oxo-1H-benzimidazole-1-carboxamide hydrochloride monohydrate and of endo-3-ethyl-2,3-dihydro-N-(8-methyl-8-azabicyclo (3.2.1) oct-3-yl)-2-oxo-1H-benzimidazole-1-carboxamide hydrochloride monohydrate as 5-HT antagonists | BOEHRINGER INGELHEIM ITALIA (IT) | 1998-07-29 | — | — | EP | claimed |
| US-5552408-A | Benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 1996-09-03 | — | — | US | claimed |
| EP-0523013-B1 | Use of benzimidazoline-2-oxo-1-carboxylic acid derivatives in the treatment of organic mental diseases | BOEHRINGER INGELHEIM ITALIA (IT) | 1994-12-21 | — | — | EP | claimed |
| US-5358954-A | Antiserotonine agent, antiemetic, gastrointestinal disorders | BOEHRINGER INGELHEIM ITALIA (IT) | 1994-10-25 | — | — | US | claimed |
| EP-0567767-A1 | Crystalline forms of endo-2,3-dihydro-N-(8-methyl-8-azabicyclo 3.2.1 oct-3-yl)-2-oxo-1H-benzimidazole-1-carboxamide hydrochloride monohydrate and of endo-3-ethyl-2,3-dihydro-N-(8-methyl-8-azabicyclo 3.2.1 oct-3-yl)-2-oxo-1H-benzimidazole-1-carboxamide hydrochloride monohydrate as 5-HT antagonists | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 1993-11-03 | — | — | EP | claimed |
| US-5223511-A | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 1993-06-29 | — | — | US | claimed |
| EP-0523013-A2 | Use of benzimidazoline-2-oxo-1-carboxylic acid derivatives in the treatment of organic mental diseases | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 1993-01-13 | — | — | EP | claimed |
| JP-6073053-A | — | — | None | — | — | JP | disclosed |
| EP-1239882-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND 5HT3 AGONISTS | GLAXO GROUP LTD (GB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030018008-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-23 | — | — | US | disclosed |
| EP-0851756-B1 | USE OF ONDANSETRON IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TREMOR | GLAXO GROUP LTD (GB) | 2003-01-15 | — | — | EP | disclosed |
| US-6506580-B1 | Gastrointestinal, nervous system and cardiovascular disorders; Alzheimer*s and Parkinson*s disease; antiarrhythmia agents, cognition activators | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2003-01-14 | — | — | US | disclosed |
| WO-1994013284-A1 | NEW USE OF 5-HT3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 1994-06-23 | — | — | WO | disclosed |
| JP-H0673053-A | CRYSTALLINE MONOHYDRATES OF ENDO-2,3-DIHYDRO-N-(8-METHYL-8-AZABICYCLO(3.2.1)OCT-3-YL)2-OXO-1H-BENZIMIDAZOLE-1-CARBOXAMIDE HYDROCHLORIDE AND ENDO-3-ETHYL-2,3-DIHYDRO-N-(8-METHYL-8-AZABICYCLO(3.2.1)OCT-3-YL)-2-OXO-1H-BENZIMIDAZOLE-1-CARBOXYAMIDE HYDROCHLORIDE | BOEHRINGER INGELHEIM IT SPA | 1994-03-15 | — | — | JP | disclosed |
| EP-0567767-A1 | Crystalline forms of endo-2,3-dihydro-N-(8-methyl-8-azabicyclo 3.2.1 oct-3-yl)-2-oxo-1H-benzimidazole-1-carboxamide hydrochloride monohydrate and of endo-3-ethyl-2,3-dihydro-N-(8-methyl-8-azabicyclo 3.2.1 oct-3-yl)-2-oxo-1H-benzimidazole-1-carboxamide hydrochloride monohydrate as 5-HT antagonists | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 1993-11-03 | — | — | EP | disclosed |
| EP-0567767-A1 | Crystalline forms of endo-2,3-dihydro-N-(8-methyl-8-azabicyclo 3.2.1 oct-3-yl)-2-oxo-1H-benzimidazole-1-carboxamide hydrochloride monohydrate and of endo-3-ethyl-2,3-dihydro-N-(8-methyl-8-azabicyclo 3.2.1 oct-3-yl)-2-oxo-1H-benzimidazole-1-carboxamide hydrochloride monohydrate as 5-HT antagonists | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 1993-11-03 | — | — | EP | disclosed |
| US-5223511-A | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 1993-06-29 | — | — | US | disclosed |
| EP-0523013-A2 | Use of benzimidazoline-2-oxo-1-carboxylic acid derivatives in the treatment of organic mental diseases | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 1993-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018008-A1 | Formulations of adenosine a1 agonists | ADORA1, ADORA3, ADORA2A | HTR4 33/4885HTR3A 6/4885TMEM97 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.